Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
Filing tables
Filing exhibits
Related press release
APRE similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) | Registration Statement (Form S-8 No. 333-234765) pertaining to the 2019 Long Term Equity Incentive Plan of Aprea Therapeutics, Inc., |
(2) | Registration Statement (Form S-8 No. 333-250043) pertaining to the 2019 Long Term Equity Incentive Plan of Aprea Therapeutics, Inc., |
(3) | Registration Statement (Form S-3/A No. 333-250041) of Aprea Therapeutics, Inc. |
of our reports dated March 16, 2021, with respect to the consolidated financial statements of Aprea Therapeutics, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2020.
/s/ Ernst & Young LLP
Iselin, New Jersey
March 16, 2021